Cipla inks pacts to invest in iCaltech Innovations

Written by Ruchika Sharma Published On 2025-07-22T16:02:22+05:30 | Updated On 22 July 2025 4:02 PM IST

Cipla profit up 3.7 percent at Rs 1353 crore in Q2

Mumbai: Cipla Limited has announced that it has signed definitive agreements for investment in Optionally Convertible Preference Shares of iCaltech Innovations Private Limited, subject to completion of certain conditions.

iCaltech is engaged in the design, development, and commercialisation of diagnostic medical equipment and apparatus, with a core focus on respiratory care.

Commenting on the development, Mr. Achin Gupta, Global COO, Cipla Limited said, “As lung leaders, our decision to invest in iCaltech reflects Cipla's commitment to advancing respiratory diagnostics. With the aim to reduce the existing gap in the current ecosystem, our strategic funding will enable iCaltech to further expand and develop innovative devices. We remain committed towards providing easy access to high-quality diagnostic solutions across India.”

"Strategic partnerships remain central to Cipla’s innovation engine, as the company continues to expand its digital, devices and diagnostics offerings and build on its legacy of lung leadership," Cipla stated in a release.

iCaltech is a Bangalore based ISO 13485 certified Medical Devices Company. iCaltech conceptualises, develops, manufactures and markets Regulatory approved Medical Diagnostic Products. iCaltech conceptualises, develops, manufactures and markets Regulatory approved Medical Diagnostic Products.

Established in 1935, Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolio in its home markets of India, South Africa, North America, and key regulated and emerging markets. The company strengths lies in the respiratory, anti-retroviral, urology, cardiology, antiinfective and CNS segments. Cipla 46 manufacturing sites around the world produce 50+ dosage forms and 1,500+ products using cutting-edge technology platforms to cater to our 74+ markets.

Read also: Cipla Secures CDSCO Panel Nod to Manufacture Amantadine Oral Solution with Trial Waiver

ciplacipla newsinvestmentiCaltech Innovations

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751